Patient ||| S:0 E:7 ||| NN
,  ||| S:7 E:9 ||| ,
tumor  ||| S:9 E:15 ||| NN
and  ||| S:15 E:19 ||| CC
therapeutic  ||| S:19 E:31 ||| JJ
features  ||| S:31 E:40 ||| NNS
related  ||| S:40 E:48 ||| VBN
to  ||| S:48 E:51 ||| TO
recurrence  ||| S:51 E:62 ||| VB
of  ||| S:62 E:65 ||| IN
ductal  ||| S:65 E:72 ||| JJ
carcinoma  ||| S:72 E:82 ||| NN
in  ||| S:82 E:85 ||| IN
situ  ||| S:85 E:90 ||| NNS
( ||| S:90 E:91 ||| -LRB-
DCIS ||| S:91 E:95 ||| NNP
)  ||| S:95 E:97 ||| -RRB-
To  ||| S:97 E:100 ||| TO
evaluate  ||| S:100 E:109 ||| VB
the  ||| S:109 E:113 ||| DT
correlations  ||| S:113 E:126 ||| NN
between  ||| S:126 E:134 ||| IN
patient ||| S:134 E:141 ||| NN
,  ||| S:141 E:143 ||| ,
tumor  ||| S:143 E:149 ||| NN
and  ||| S:149 E:153 ||| CC
therapeutic  ||| S:153 E:165 ||| JJ
features  ||| S:165 E:174 ||| NNS
and  ||| S:174 E:178 ||| CC
DCIS  ||| S:178 E:183 ||| NNP
recurrence  ||| S:183 E:194 ||| NN
after  ||| S:194 E:200 ||| IN
primary  ||| S:200 E:208 ||| JJ
treatment ||| S:208 E:217 ||| NN
,  ||| S:217 E:219 ||| ,
a  ||| S:219 E:221 ||| DT
cohort  ||| S:221 E:228 ||| NN
of  ||| S:228 E:231 ||| IN
132  ||| S:231 E:235 ||| CD
cases  ||| S:235 E:241 ||| NNS
of  ||| S:241 E:244 ||| IN
DCISs ||| S:244 E:249 ||| NNP
,  ||| S:249 E:251 ||| ,
treated  ||| S:251 E:259 ||| VBN
at  ||| S:259 E:262 ||| IN
Prof.  ||| S:262 E:268 ||| NNP
Dr.  ||| S:268 E:272 ||| NNP
Ion  ||| S:272 E:276 ||| NNP
Chiricuta  ||| S:276 E:286 ||| NNP
Oncology  ||| S:286 E:295 ||| NNP
Institute ||| S:295 E:304 ||| NNP
,  ||| S:304 E:306 ||| ,
Cluj-Napoca ||| S:306 E:317 ||| NNP
,  ||| S:317 E:319 ||| ,
Romania ||| S:319 E:326 ||| NNP
,  ||| S:326 E:328 ||| ,
between  ||| S:328 E:336 ||| IN
1999  ||| S:336 E:341 ||| CD
and  ||| S:341 E:345 ||| CC
2010 ||| S:345 E:349 ||| CD
,  ||| S:349 E:351 ||| ,
were  ||| S:351 E:356 ||| VBD
studied ||| S:356 E:363 ||| VBN
.  ||| S:363 E:365 ||| .
Present  ||| S:365 E:373 ||| JJ
study  ||| S:373 E:379 ||| NN
showed  ||| S:379 E:386 ||| VBD
that  ||| S:386 E:391 ||| DT
age  ||| S:391 E:395 ||| NN
< ||| S:395 E:396 ||| SYM
45  ||| S:396 E:399 ||| CD
years  ||| S:399 E:405 ||| NNS
at  ||| S:405 E:408 ||| IN
diagnosis  ||| S:408 E:418 ||| NN
and  ||| S:418 E:422 ||| CC
presence  ||| S:422 E:431 ||| NN
of  ||| S:431 E:434 ||| IN
the  ||| S:434 E:438 ||| DT
necrosis  ||| S:438 E:447 ||| NN
were  ||| S:447 E:452 ||| VBD
significantly  ||| S:452 E:466 ||| RB
correlated  ||| S:466 E:477 ||| VBN
with  ||| S:477 E:482 ||| IN
recurrence ||| S:482 E:492 ||| NN
,  ||| S:492 E:494 ||| ,
meanwhile  ||| S:494 E:504 ||| RB
nuclear  ||| S:504 E:512 ||| JJ
grade  ||| S:512 E:518 ||| NN
is  ||| S:518 E:521 ||| VBZ
significantly  ||| S:521 E:535 ||| RB
correlated  ||| S:535 E:546 ||| VBN
with  ||| S:546 E:551 ||| IN
quicker  ||| S:551 E:559 ||| RBR
relapse  ||| S:559 E:567 ||| JJ
meaning  ||| S:567 E:575 ||| NN
that  ||| S:575 E:580 ||| IN
for  ||| S:580 E:584 ||| IN
high-grade  ||| S:584 E:595 ||| JJ
lesions  ||| S:595 E:603 ||| JJ
recurrence  ||| S:603 E:614 ||| NN
occurs  ||| S:614 E:621 ||| VBZ
usually  ||| S:621 E:629 ||| RB
during  ||| S:629 E:636 ||| IN
the  ||| S:636 E:640 ||| DT
first  ||| S:640 E:646 ||| JJ
36  ||| S:646 E:649 ||| CD
months  ||| S:649 E:656 ||| NNS
of  ||| S:656 E:659 ||| IN
follow-up ||| S:659 E:668 ||| NNP
,  ||| S:668 E:670 ||| ,
meanwhile  ||| S:670 E:680 ||| RB
for  ||| S:680 E:684 ||| IN
non-high-grade  ||| S:684 E:699 ||| JJ
lesions  ||| S:699 E:707 ||| NNS
recurrence  ||| S:707 E:718 ||| VBP
usually  ||| S:718 E:726 ||| RB
occurs  ||| S:726 E:733 ||| VBZ
after  ||| S:733 E:739 ||| IN
36  ||| S:739 E:742 ||| CD
months  ||| S:742 E:749 ||| NNS
of  ||| S:749 E:752 ||| IN
follow-up ||| S:752 E:761 ||| JJ
.  ||| S:761 E:763 ||| .
Also ||| S:763 E:767 ||| RB
,  ||| S:767 E:769 ||| ,
the  ||| S:769 E:773 ||| DT
study  ||| S:773 E:779 ||| NN
showed  ||| S:779 E:786 ||| VBD
that  ||| S:786 E:791 ||| IN
a  ||| S:791 E:793 ||| DT
important  ||| S:793 E:803 ||| JJ
factor  ||| S:803 E:810 ||| NN
correlated  ||| S:810 E:821 ||| NN
with  ||| S:821 E:826 ||| IN
recurrence  ||| S:826 E:837 ||| NN
( ||| S:837 E:838 ||| -LRB-
both  ||| S:838 E:843 ||| DT
local  ||| S:843 E:849 ||| JJ
and  ||| S:849 E:853 ||| CC
overall ||| S:853 E:860 ||| JJ
)  ||| S:860 E:862 ||| -RRB-
for  ||| S:862 E:866 ||| IN
patients  ||| S:866 E:875 ||| NNS
treated  ||| S:875 E:883 ||| VBN
with  ||| S:883 E:888 ||| IN
breast  ||| S:888 E:895 ||| JJ
conservative  ||| S:895 E:908 ||| JJ
surgery  ||| S:908 E:916 ||| NN
( ||| S:916 E:917 ||| -LRB-
BCS ||| S:917 E:920 ||| NNP
)  ||| S:920 E:922 ||| -RRB-
was  ||| S:922 E:926 ||| VBD
the  ||| S:926 E:930 ||| DT
status  ||| S:930 E:937 ||| NN
of  ||| S:937 E:940 ||| IN
the  ||| S:940 E:944 ||| DT
resection  ||| S:944 E:954 ||| JJ
margins  ||| S:954 E:962 ||| NNS
as  ||| S:962 E:965 ||| IN
well  ||| S:965 E:970 ||| RB
as  ||| S:970 E:973 ||| IN
the  ||| S:973 E:977 ||| DT
association  ||| S:977 E:989 ||| NN
of  ||| S:989 E:992 ||| IN
adjuvant  ||| S:992 E:1001 ||| JJ
radiotherapy ||| S:1001 E:1013 ||| NN
.  ||| S:1013 E:1015 ||| .
Overall  ||| S:1015 E:1023 ||| JJ
recurrence  ||| S:1023 E:1034 ||| NN
rate  ||| S:1034 E:1039 ||| NN
was  ||| S:1039 E:1043 ||| VBD
9. ||| S:1043 E:1045 ||| CD
( ||| S:1045 E:1046 ||| -LRB-
84 ||| S:1046 E:1048 ||| CD
) ||| S:1048 E:1049 ||| -RRB-
%  ||| S:1049 E:1051 ||| NN
and  ||| S:1051 E:1055 ||| CC
during  ||| S:1055 E:1062 ||| IN
a  ||| S:1062 E:1064 ||| DT
mean  ||| S:1064 E:1069 ||| JJ
follow-up  ||| S:1069 E:1079 ||| NN
of  ||| S:1079 E:1082 ||| IN
62.99  ||| S:1082 E:1088 ||| CD
months  ||| S:1088 E:1095 ||| NNS
with  ||| S:1095 E:1100 ||| IN
limits  ||| S:1100 E:1107 ||| NNS
between  ||| S:1107 E:1115 ||| IN
24  ||| S:1115 E:1118 ||| CD
( ||| S:1118 E:1119 ||| -LRB-
imposed  ||| S:1119 E:1127 ||| VBN
by  ||| S:1127 E:1130 ||| IN
study ||| S:1130 E:1135 ||| NN
)  ||| S:1135 E:1137 ||| -RRB-
and  ||| S:1137 E:1141 ||| CC
153  ||| S:1141 E:1145 ||| CD
months ||| S:1145 E:1151 ||| NNS
,  ||| S:1151 E:1153 ||| ,
standard  ||| S:1153 E:1162 ||| JJ
deviation  ||| S:1162 E:1172 ||| NN
29.28 ||| S:1172 E:1177 ||| NN
.  ||| S:1177 E:1179 ||| .
